Land: Nýja-Sjáland
Tungumál: enska
Heimild: Medsafe (Medicines Safety Authority)
Cyproterone acetate 2mg; Ethinylestradiol 0.035mg (micronised)
Viatris Limited
Cyproterone acetate 2 mg
2mg/0.035mg
Film coated tablet
Active: Cyproterone acetate 2mg Ethinylestradiol 0.035mg (micronised) Excipient: Ethanol Lactose monohydrate Magnesium stearate Maize starch Opadry pink 03F540049 Povidone Purified talc Purified water
Prescription
Zhejiang Xianju Xianle Pharmaceutical Co Ltd
Danica 35 is indicated for the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. Danica 35 will also provide effective contraception in this patient group. It should not be used in combination with other hormonal contraceptives (see Section 4.3). Danica 35 is also indicated for the relief of symptoms of polycystic ovary syndrome.
Package - Contents - Shelf Life: Blister pack, PVC/PVdC/Alu foil 21 tablet packed 3-off in secondary carton - 63 tablets - 36 months from date of manufacture stored at or below 25°C
2014-01-10